Comparison of positive rate of peritoneal dialysis-associated peritonitis pathogens cultured by traditional method and modified method and analysis of drug resistance

Chen Chunmiao, Xu Zhihui, Wang Feifei, Yun Xiaoying, Li Bing

PDF(622 KB)
Chinese Journal of Nephrology ›› 2024, Vol. 40 ›› Issue (4) : 300-304. DOI: 10.3760/cma.j.cn441217-20230809-00809
Short Original Article

Comparison of positive rate of peritoneal dialysis-associated peritonitis pathogens cultured by traditional method and modified method and analysis of drug resistance

Author information +
History +

Abstract

It was a retrospective cohort study. Peritoneal dialysis exudate samples from patients diagnosed with peritoneal dialysis-associated peritonitis (PDAP) in the Nephrology Department of the Second Affiliated Hospital of Hainan Medical College from January 1, 2021 to December 31, 2022 were collected. Based on different time of peritonitis, the specimens were split into two groups: the traditional method group and the modified method group. Only the traditional method was used for pathogen culture in the traditional method group. Both the traditional method and modified method were used for pathogen culture in the modified method group. The rates of positive culture of pathogenic bacteria, duration required to obtain positive culture results, spectrum of pathogenic bacteria, and drug resistance were analyzed. The results showed that a total of 223 patients (324 cases) with PDAP were included in the study, including 115 patients (168 cases) in the traditional method group and 108 patients (156 cases) in the modified method group. The modified method group displayed a significantly higher rate of pathogenic bacteria than the traditional method group [84.62% (132/156) vs. 69.23% (108/156), χ2 =18.903, P<0.001]. Additionally, the modified method group required less time to achieve a positive culture result of pathogenic bacteria than the traditional method group [69.0 (58.0, 90.9) h vs. 79.5 (65.6, 90.2) h, Z=2.061, P=0.039]. In this study, 120 culture-positive pathogens were identified in the traditional method group, of which, 69 (57.50%) were Gram-positive, 46 (38.33%) were Gram-negative, and 5 (4.17%) were fungi; The common strains of Gram-positive bacteria were staphylococcus epidermidis (17 strains, 14.17%) and streptococcus salivarius (10 strains, 8.33%). There were 134 culture-positive pathogens identified in the modified method group, of which 106 (79.10%) were Gram⁃positive, 24 (17.91%) were Gram⁃negative, and 4 (2.99%) were fungi; The common strains of Gram-positive bacteria were streptococcus salivarius (20 strains, 14.93%) and staphylococcus epidermidis (15 strains, 11.19%). Gram-positive bacteria had the highest resistance rate to oxacillin (50/85, 58.82%), Gram-negative bacteria had the highest resistance rate to ampicillin (21/35, 60.00%), and fungi was only resistant to fluconazole (1/9, 11.11%). The study suggests that the modified method can increase the positive rate of pathogen culture and shorten the culture time in peritoneal dialysate effluent. Gram⁃positive cocci are the main pathogenic bacteria of PDAP in this center. Oxacillin and ampicillin should not be the first choice for the treatment of PDAP in this center.

Key words

Peritoneal dialysis / Peritonitis / Drug resistance, bacterial / Pathogenic bacteria / Culture method

Cite this article

Download Citations
Chen Chunmiao. , Xu Zhihui. , Wang Feifei. , Yun Xiaoying. , Li Bing. Comparison of positive rate of peritoneal dialysis-associated peritonitis pathogens cultured by traditional method and modified method and analysis of drug resistance[J]. Chinese Journal of Nephrology, 2024, 40(4): 300-304. DOI: 10.3760/cma.j.cn441217-20230809-00809.
腹膜透析(peritoneal dialysis,PD)相关性腹膜炎(PD⁃associated peritonitis,PDAP)是PD中常见且病情严重的并发症,是PD患者死亡的主要原因,文献报道>15%的PD患者死于PDAP1。透出液病原菌培养是诊断PDAP并指导抗生素应用的重要手段。然而,透出液病原菌培养阳性率低和抗生素耐药日益严重是PDAP临床诊治中面临的两大难题2-3。国际腹膜透析协会(International Society for Peritoneal Dialysis,ISPD)建议,当透出液病原菌培养阴性率>15%时应重新评估和改进培养方法3。我们通过分析和比较海南医学院第二附属医院PD中心PDAP患者PD透出液的传统法和改良法病原菌培养阳性率,并分析了病原菌谱和耐药情况,以期为合理指导临床用药提供依据。

一 对象与方法

1. 研究对象:本研究为回顾性队列研究。研究对象为2021年1月1日至2022年12月31日在海南医学院第二附属医院PD中心临床诊断为PDAP的患者。纳入标准:(1)接受持续性非卧床PD治疗的PDAP患者;(2)PDAP诊断符合ISPD制订的诊断标准3;(3)患者发生腹膜炎的时间明确。排除标准:(1)临床资料不完整;(2)未行PD透出液病原菌培养检查。本研究获得海南医学院第二附属医院伦理委员会批准(伦理批准编号:LW2020321)。患者或授权家属签署知情同意书。
2. 研究方案:根据腹膜炎发生的不同时间分为传统法组和改良法组,传统法组为2021年收治的PDAP患者,改良法组为2022年收治的PDAP患者。传统法组PD透出液样本仅采用传统法进行病原菌的培养,改良法组PD透出液样同时采用传统法和改良法进行病原菌的培养。留取样本前PD透出液留腹时间≥6 h,出现浑浊的首袋透出液为样本采集的首选。传统法透出液收集方法:整袋透出液静置1 h后摇晃混匀15 min,用无菌注射器抽取透出液样本10 ml直接注入血培养瓶中培养。改良法透出液收集方法:悬挂静置整袋透出液1 h后,用无菌注射器从底部抽取100 ml透出液样本分别注入2个50 ml无菌离心管中,3 000×g离心15 min,去上清后取两管沉渣分别用5 ml 0.9%氯化钠溶液悬浮后再注入血培养瓶培养。使用全自动血培养仪在37 ℃环境下培养。阳性结果样本采用全自动微生物分析仪进行菌种鉴定和药敏试验分析。药敏试验采用纸片扩散法,判断标准参照美国国家临床实验室标准委员会标准。如果培养7 d无菌生长视为阴性结果。
3. 资料收集:收集患者性别、年龄、原发疾病、透析龄、合并疾病[包括糖尿病、高血压、心脑血管疾病(包括冠心病、心力衰竭、脑出血和脑梗死)]等人口学和临床资料。比较两种方法病原菌培养阳性率、培养阳性时间,并分析2组患者疾病转归、病原菌谱和耐药情况。
4. 统计学方法:采用SPSS 25.0软件进行数据的统计分析。正态分布的计量资料采用x-±s形式表示,2组间比较采用独立样本t检验;非正态分布的计量资料采用MP 25P 75)形式表示,2组间比较采用Mann⁃Whitney U检验。计数资料采用例数和/或百分比表示,2组间比较采用χ 2检验,配对资料的比较采用McNemar检验。P<0.05被认为差异有统计学意义。

二 结果

1. 基线资料:共223例(324例次)PDAP患者被纳入本研究,传统法组115例(168例次),改良法组108例(156例次)。传统法组和改良法组在年龄[(54.6±15.4)岁比(56.2±14.6)岁,t=0.980,P=0.328]、性别(男性:92例次比115例次,女性:64例次比53例次,χ 2 =3.150,P=0.076)、透析龄[13.8(4.1,30.0)个月比16.6(5.0,34.2)个月,Z=0.667,P=0.505]、腹膜炎次数(1次者76例次比80例次,χ 2 =0.017,P=0.896;2次者21例次比24例次,χ 2 =0.070,P=0.791;≥3次者为11例次比11例次,χ 2 =0.024,P=0.877)、原发病为糖尿病肾病(32例次比46例次,χ 2 =2.087,P=0.149)、慢性肾小球肾炎(62例次比60例次,χ 2 =0.559,P=0.454)、合并糖尿病(46例次比38例次,χ 2 =0.385,P=0.535)、高血压(56例次比67例次,χ 2 =3.175,P=0.075)及心脑血管疾病(37例次比29例次,χ 2 =0.588,P=0.443)的差异均无统计学意义。
2. 改良法组两种培养方法病原菌培养阳性率及培养阳性时间比较:改良法培养结果显示,病原菌培养阳性132例次,培养阴性24例次,培养阳性率为84.62%(132/156)。传统法培养结果显示,病原菌培养阳性108例次,培养阴性48例次,培养阳性率为69.23%(108/156)。两种方法病原菌培养阳性率的比较差异有统计学意义(χ2 =18.903,P<0.001)。传统法病原菌培养阳性时间为79.5(65.6,90.2)h,改良法培养阳性时间为69.0(58.0,90.9)h,差异有统计学意义(Z=2.061,P=0.039)。见表1
表1 改良法组传统法和改良法病原菌培养阳性率及培养阳性时间比较
组别

培养阳性

[例次(%)]

培养阴性

[例次(%)]

培养阳性时间

[h,MP 25P 75)]

改良法组(n=156) 132(84.62) 24(15.38) 69.0(58.0,90.9)
传统法组(n=156) 108(69.23) 48(30.77) 79.5(65.6,90.2)
统计量(χ 2/Z 18.903 2.061
P <0.001 0.039
3. 2组PDAP患者的病原菌分布情况:2021年传统法组共培养病原菌120株,其中革兰阳性(G+)菌69株(57.50%),革兰阴性(G-)菌46株(38.33%),真菌5株(4.17%)。G+菌中常见菌株为表皮葡萄球菌17株(14.17%)和唾液链球菌10株(8.33%);G-菌中常见菌株为大肠杆菌15株(12.50%)和肺炎克雷伯菌10株(8.33%);真菌中常见菌株为白念珠菌2株(1.67%)。2022年改良法组共培养病原菌134株,其中G+菌106株(79.10%),G-菌24株(17.91%),真菌4株(2.99%)。G+菌中常见菌株为唾液链球菌20株(14.93%)和表皮葡萄球菌15株(11.19%);G-菌中常见菌株为大肠杆菌13株(9.70%)和肺炎克雷伯菌4株(2.99%);真菌中常见菌株为光滑念珠菌2株(1.49%)。见图1
图1 2021年传统法组(A、C)与2022年改良法组(B、D)腹膜透析相关性腹膜炎患者的病原菌分布(n=254)

Full size|PPT slide

4. 病原菌耐药情况:药敏试验结果显示,G+菌感染患者中,苯唑西林耐药率最高(50/85,58.82%),其次是红霉素(81/153,52.94%)、青霉素G(77/148,52.03%),未发现病原菌对达托霉素、替考拉宁、利奈唑胺和万古霉素耐药。G-菌感染患者中,氨苄西林耐药率最高(21/35,60.00%),其次是头孢唑林(19/44,43.18%)、莫西沙星(18/47,38.30%),未发现病原菌对厄他培南、美罗培南及替加环素耐药。真菌感染患者中,仅发现对氟康唑耐药(1/9,11.11%)。见表2
表2 腹膜透析透出液样本病原菌药敏试验结果
抗生素 敏感(株) 中介(株) 耐药(株)

耐药率

[%(构成比)]

革兰阳性菌(n=175)
苯唑西林 34 1 50 58.82(50/85)
红霉素 69 3 81 52.94(81/153)
青霉素G 50 21 77 52.03(77/148)
头孢唑林 69 4 78 51.66(78/151)
克拉霉素 50 0 45 47.37(45/95)
革兰阴性菌(n=70)
氨苄西林 14 0 21 60.00(21/35)
头孢唑啉 23 2 19 43.18(19/44)
莫西沙星 29 0 18 38.30(18/47)
复方新诺明 36 0 22 37.93(22/58)
氯霉素 35 3 19 33.33(19/57)
真菌(n=9)
氟康唑 7 1 1 11.11(1/9)
注:此表数据仅显示耐药率排名前5名的抗生素
5. 疾病转归:2021年传统法组共纳入115例PDAP患者,剔除自动出院3例,最终112例患者被纳入本研究,其中退出PD 23例(20.54%),包括转血液透析19例(16.96%)和死亡4例(3.57%),89例(79.46%)患者治愈。2022年改良法组共纳入108例PDAP患者,剔除自动出院7例,最终101例患者被纳入本研究,其中退出PD 17例(16.83%),包括转血液透析8例(7.92%)和死亡9例(8.91%),84例(83.17%)患者治愈。2组在转血液透析人数的差异有统计学意义(19/112比8/101,χ 2=3.924,P=0.048),而退出PD人数、死亡人数、治愈人数的差异均无统计学意义(均P>0.05)。

三 讨论

PD是终末期肾病患者肾脏替代治疗方法之一,而腹膜炎是PD技术失败和转血液透析的主要原因,严重或长期的腹膜炎会导致腹膜结构和功能改变,最终导致腹膜衰竭1。相关研究表明,G-菌腹膜炎发病率与温度、湿度呈正相关4。海南省地处热带气候,全年平均温度和湿度均高于大部分内陆地区,这给本地区PD管理增加了难度。据统计,本中心PDAP导致的治疗失败率和病死率分别达12.59%、6.67%,高于内陆地区报道5。鉴于本地区的特殊性,及早发现感染并及时治疗对PD管理尤为重要。
病原体检测是指导临床PDAP治疗的关键。ISPD建议病原菌培养阴性率应小于15%。多项研究表明,将离心后的PD透出液接种至血培养瓶能获得更高的培养阳性率6-7。杨君等8发现悬挂+离心法培养阳性率高于单纯离心法培养,但该研究未进行同一样本对照,其研究结果仍需要进一步验证。本中心既往采用传统法培养,其培养阴性率未达到ISPD建议的推荐值,仍需探索新的培养方法。本研究采用的改良法利用重力和向心力的作用使PD透出液样本浓缩,提高了样本浓度,结果显示,改良法病原菌培养阳性率为84.62%,较传统法明显改善,且高于中国大部分大型的PD中心的报道数据8-9。同时,我们比较了两种培养方法的培养阳性时间,结果显示改良法培养阳性时间短于传统法(P=0.039),说明改良法不仅提高了培养阳性率,还缩短了培养时间。在疾病转归中我们发现,改良法组转血液透析比例低于传统法组,表明改良法可能一定程度上改善了PD患者的预后。美中不足的是,本研究探索的改良法培养阴性率仍未能达到ISPD的要求,原因可能为:(1)患者送检前已使用抗生素;(2)样本留取、送检时间过长;(3)与非典型病原体等罕见感染有关。
本研究共培养出病原菌254株,其中多重致病菌感染7例次,其临床转归显示,2例患者转血液透析,1例患者死亡。据法国最新的一项研究报道,肠道病原菌在多菌性腹膜炎中的分离率高于单一微生物腹膜炎,而较差的预后与肠道病原体的分离相关10。与国内外相关研究结果基本一致911,本研究G+球菌为主要致病菌,其中传统法组以凝固酶阴性葡萄球菌(coagulase⁃negative staphylococci,CoNS)——表皮葡萄球菌为主,改良法组以唾液链球菌为主。CoNS感染往往与患者换液操作过程中的污染相关,而接触污染是PDAP的最常见原因12。因此,ISPD建议感染后应进行操作再次培训及考核3。唾液链球菌感染多见于操作者在更换PD液时未佩戴口罩。链球菌感染治愈率大于85%,多数患者不需要拔除PD导管3。本中心链球菌感染患者均可治愈,但仍应加强宣教,提高患者操作时佩戴口罩的意识,避免感染。本研究G-菌中,两种培养方法均以大肠杆菌为主。大肠杆菌为机会致病菌,多发生在急性胃肠炎或长期便秘的患者中。因此,发现便秘、腹泻等症状时应及时就医,避免病情加重造成腹膜炎。真菌感染较少见,传统法组以白念珠菌为主,改良法组以光滑念珠菌为主。真菌性腹膜炎患者死亡风险极高,本研究9例真菌性腹膜炎患者中有3例死亡。一旦确诊,应立即拔除PD导管并开始抗真菌治疗。
本研究显示G+菌对苯唑西林的耐药率最高(58.82%),其次为红霉素、青霉素G、头孢唑林(均>50%)。G+菌中最常见为CoNS,国内外研究也表明CoNS对苯唑西林耐药率最高(70%),但耐甲氧西林菌株也不容忽视13。G-菌对氨苄西林的耐药率最高(60.00%),其次是头孢唑林(43.18%)。G-菌中最常见的是大肠杆菌。国内大样本研究显示,随着时间推移,大肠杆菌对头孢唑啉、环丙沙星的耐药性升高14。真菌仅对氟康唑耐药(11.11%)。因此以上抗生素不宜作为本中心治疗PDAP的首选用药。
本研究存在一些局限性。首先,本研究为单中心研究,研究结论需多中心大样本的研究加以验证;其次,本研究仅比较2年病原菌分布情况,时间跨度小,对本中心PDAP病原菌变化趋势需要后续长时间跨度的研究进一步探讨。
综上所述,改良法培养PD透出液既可以提高培养阳性率,又可以缩短培养时间,为临床提供了新的选择。G+球菌是本中心PDAP的主要病原菌,但不同时期的细菌谱可能存在差异。

References

1
Szeto CC, Li PK. Peritoneal dialysis-associated peritonitis[J]. Clin J Am Soc Nephrol, 2019, 14(7): 1100-1105. DOI: 10.2215/CJN.14631218 .
2
Wilkie M, Szeto CC. Rising to the challenge of antimicrobial resistance[J]. Perit Dial Int, 2017, 37(2): 129-130. DOI: 10.3747/pdi.2016.00277 .
3
Li PK, Chow KM, Cho Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment[J]. Perit Dial Int, 2022, 42(2): 110-153. DOI: 10.1177/08968608221080586 .
4
张少贵, 赵慧萍, 武蓓, 等. 季节变化与腹膜透析患者发生腹膜透析相关性腹膜炎的关系[J]. 中华肾脏病杂志, 2017, 33(7): 488-494. DOI: 10.3760/cma.j.issn.1001-7097. 2017.07.002 .
5
王娟, 李彧, 曹宁家, 等. 293例腹膜透析相关性腹膜炎的致病菌及其耐药性分析[J]. 浙江医学, 2020, 42(19): 2102- 2105. DOI: 10.12056/j.issn.1006-2785.2020.42.19.2020- 1544 .
6
Pindi G, Kawle V, Sunkara RR, et al. Continuous ambulatory peritoneal dialysis peritonitis: microbiology and outcomes[J]. Indian J Med Microbiol, 2020, 38(1): 72-77. DOI: 10.4103/ijmm.IJMM_20_251 .
7
Tanratananon D, Deekae S, Raksasuk S, et al. Evaluation of different methods to improve culture-negative peritoneal dialysis-related peritonitis: a single-center study[J]. Ann Med Surg (Lond), 2021, 63: 102139. DOI: 10.1016/j.amsu.2021.01.087 .
8
杨君, 赵丽娟, 许国双, 等. 提高腹膜透析相关性腹膜炎培养阳性率方法探究[J]. 中华现代护理杂志, 2019, 25(33): 4287-4290. DOI: 10.3760/cma.j.issn.1674-2907.2019. 33.006 .
9
佟怡婧, 严豪, 李振元, 等. 711例次腹膜透析相关性腹膜炎的致病菌谱变化及药物敏感分析[J]. 中华肾脏病杂志, 2017, 33(8): 601-608. DOI: 10.3760/cma.j.issn.1001- 7097.2017.08.007 .
10
Forté V, Novelli S, Zaidan M, et al. Microbiology and outcomes of polymicrobial peritonitis associated with peritoneal dialysis: a register-based cohort study from the French Language Peritoneal Dialysis Registry[J]. Nephrol Dial Transplant, 2023, 38(5): 1271-1281. DOI: 10.1093/ndt/gfac267 .
11
Yin S, Tang M, Rao Z, et al. Risk factors and pathogen spectrum in continuous ambulatory peritoneal dialysis- associated peritonitis: a single center retrospective study[J]. Med Sci Monit, 2022, 28: e937112. DOI: 10.12659/MSM.937112 .
12
Campbell DJ, Johnson DW, Mudge DW, et al. Prevention of peritoneal dialysis-related infections[J]. Nephrol Dial Transplant, 2015, 30(9): 1461-1472. DOI: 10.1093/ndt/gfu313 .
13
Cho Y, Struijk DG. Peritoneal dialysis-related peritonitis: atypical and resistant organisms[J]. Semin Nephrol, 2017, 37(1): 66-76. DOI: 10.1016/j.semnephrol.2016.10.008 .
14
Wu H, Yi C, Zhang D, et al. Changes of antibiotic resistance over time among Escherichia coli peritonitis in Southern China[J]. Perit Dial Int, 2022, 42(2): 218- 222. DOI: 10.1177/08968608211045272 .

Footnotes

http://journal.yiigle.com/LinkIn.do?linkin_type=cma&DOI=10.3760/cma.j.cn441217-20230809-00809

陈春苗:数据收集、分析及论文撰写;许志辉:数据分析指导和文章修订;王菲菲、云晓滢:数据收集;李冰:研究指导、文章修订

Funding

National Natural Science Foundation of China(82370697)
Key Research and Development Project in Hainan Province(ZDYF2020126)

RIGHTS & PERMISSIONS

Copyright by Chinese Medical Association No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission. All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
PDF(622 KB)

496

Accesses

0

Citation

Detail

Sections
Recommended

/